GLP-1 Receptor Agonists and Intraocular Pressure: A Critical Look

GLP-1 Receptor Agonists and Intraocular Pressure: A Critical Look

A recent study suggested a link between glucagon-like peptide 1 (GLP-1) receptor agonists and a slight decrease in intraocular pressure (IOP). However, a new analysis points out potential oversights in the research methodology that may affect the reliability of these findings. Key concerns include the absence of propensity score matching, inadequate consideration of metformin co-usage, and failure to account for known glaucoma risk factors like corticosteroid use. These factors could lead to inaccurate conclusions about the true impact of GLP-1 receptor agonists on IOP.
Repeated Low-Level Red-Light Therapy Effectively Slows Myopia Progression in Children

Repeated Low-Level Red-Light Therapy Effectively Slows Myopia Progression in Children

In this 12-month, multicenter randomized controlled trial, children with high myopia received either repeated low-level red-light (RLRL) therapy with single vision spectacles or single vision spectacles alone. The RLRL group demonstrated significant axial length shortening, a reduction in myopic progression, and increases in choroidal and retinal thickness, indicating that RLRL therapy is a safe and effective method for inhibiting myopia progression in children with high myopia.